This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
marijuana: Archive
Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?
by Sundeep Ganoria
AbbVie's neuroscience franchise posts strong first-half growth, with Vyalev accelerating and tavapadon poised to add another potential growth driver.
ABBVNegative Net Change BIIBNegative Net Change JNJNegative Net Change
biotechs earnings marijuana pharmaceuticals
Should You Buy ACB Stock Amid Curaleaf's Hostile Takeover Attempt?
by Sundeep Ganoria
Aurora Cannabis faces a potential Curaleaf takeover at a 45% premium, but investors must weigh the offer against ACB's standalone prospects.
ACBNegative Net Change TLRYNegative Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Should You Buy, Hold or Sell GTBIF Stock Post Q2 Earnings Release?
by Sundeep Ganoria
Green Thumb tops Q2 earnings and sales estimates, but can regulatory catalysts, buybacks and expansion plans outweigh pricing pressure and fierce competition?
GTBIFNegative Net Change TLRYNegative Net Change TRLVPositive Net Change
marijuana medical pot-stocks
JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View
by Zacks Equity Research
Jazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss, as strong oncology and neuroscience demand lifts shares.
JAZZNegative Net Change ABCLPositive Net Change HOWLPositive Net Change
biotechs earnings marijuana medical
Should You Buy, Hold or Sell SNDL Stock Post Q4 Earnings Release?
by Sundeep Ganoria
SNDL sinks after weak Q2 2026 earnings, but can cost cuts and U.S. expansion through Parallel offset ongoing cannabis and liquor headwinds?
SNDLPositive Net Change TLRYNegative Net Change GTBIFNegative Net Change
earnings marijuana medical
Is JAZZ Still the Best Cannabis Stock After Federal Rescheduling?
by Sundeep Ganoria
Jazz Pharmaceuticals pairs its FDA-approved CBD blockbuster with a diversified drug portfolio, offering medical cannabis exposure despite ongoing pipeline risks.
JAZZNegative Net Change TLRYNegative Net Change GTBIFNegative Net Change
biotechs marijuana medical
ACB Stock Down 28% in Three Months: Time to Buy the Dip or Cash Out?
by Sundeep Ganoria
Aurora Cannabis' shares plunge 28% in three months as a cautious fiscal 2027 outlook overshadows record medical cannabis growth and global expansion.
ACBNegative Net Change CGCPositive Net Change TLRYNegative Net Change
marijuana medical
VFF Stock Loses 27% in Three Months: Time to Invest or Exit?
by Sundeep Ganoria
Village Farms has slid 27% in three months despite strong international cannabis growth. Can European expansion outweigh rising competition and pricing risks?
VFFPositive Net Change TLRYNegative Net Change ACBNegative Net Change
marijuana medical pot-stocks
TLRY Plans Strategic Medical Cannabis Expansion: Time to Buy or Sell?
by Sundeep Ganoria
Tilray expands its medical cannabis strategy with HelloMD, adding virtual patient access as investors weigh growth potential against ongoing profitability challenges.
TLRYNegative Net Change CRONNegative Net Change ACBNegative Net Change
marijuana medical pot-stocks
CRON Strengthens Global Footprint: Is the Cannabis Stock Worth Buying?
by Sundeep Ganoria
Cronos Group posts 40% Q1 revenue growth, gains share in Canada and expands abroad, but fierce cannabis competition keeps investors cautious.
CRONNegative Net Change TLRYNegative Net Change ACBNegative Net Change
marijuana medical pot-stocks